1	Global Assessment of IRF8 as a Novel Cancer Biomarker					
2						
3	Daniel C. McQuaid BS ¹ ; Gauri Panse MD ¹ ; Wei-Lien Wang MD ² ;					
4	Samuel G. Katz, MD, PhD ^{1*} ; Mina L. Xu, MD ^{1*}					
5						
6 7	1 Department of Pathology, Yale New-Haven Hospital, Yale School of Medicine, New Haven, CT					
8 9 10	2 Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX					
11	* These authors contributed equally to this work					
12						
13	Conflict of interest: The authors have no conflicts of interest to disclose.					
14	Running Title: IRF8 IHC detects hematopoietic tumors					
15 16	Keywords: Myeloid sarcoma, blastic plasmacytoid dendritic neoplasms, IRF8, cancer tissue microarrays					
17						
18	Corresponding authors:					
19 20 21 22 23 24	Samuel G. Katz Email: samuel.katz@yale.edu Phone: 203-785-2757 Fax: 203-785-3583 310 Cedar Street, LH315B New Haven, CT 06510					
25 26 27 28 29 30	Mina L. Xu Email: mina.xu@yale.edu Phone: 203-737-6135 Fax: 203-785-6135 310 Cedar Street, BML116 New Haven, CT 06510					

31 Abstract

32 Interferon regulatory factor 8 (IRF8) is a member of the IRF family that is specific to the 33 hematopoietic cell and is involved in regulating the development of human monocytic and 34 dendritic-lineage cells, as well as B cells. Since its utility as a sensitive and specific monoblast 35 marker in the context of acute monocytic leukemias has been recently demonstrated, we 36 hypothesized that it may also be useful as a novel immunohistochemical marker in myeloid 37 sarcomas and blastic plasmacytoid dendritic cell neoplasms (BPDCN) with respect to their 38 differential diagnoses. In this retrospective study, we analyzed the IHC expression pattern of 39 IRF8 in 385 patient samples across 30 types of cancers, referenced to their mRNA expression 40 data available through TCGA. In addition, we assessed IRF8 in 35 myeloid sarcomas, and 13 41 BPDCNs. Twenty-four of 35 cases of myeloid sarcomas (68.5%) showed positivity for IRF8, with 42 six cases (17.1%) demonstrating IRF8 expression in the absence of CD34 and MPO. All 13 of 13 43 BPDCNs (100%) showed strong uniform expression of IRF8 and was occasionally more definitive 44 than CD123. IRF8 was negative in all desmoplastic small round cell tumors, Ewing sarcomas, 45 synovial sarcomas, and undifferentiated pleomorphic sarcomas, as well as all epithelial 46 malignancies tested except for 2 triple negative breast cancers that showed subset weak 47 staining. In conclusion, IRF8 is a novel marker helpful in identifying extranodal hematopoietic 48 tumors that can otherwise be difficult to diagnose given the broad differential diagnoses and 49 frequent loss of more common lineage-defining markers.

- 50
- 51
- 52

53 **1.0: Introduction**

54	Interferon regulatory factor 8 (IRF8) is a hematopoietic-specific member of the IRF family that is
55	essential in the commitment of myeloid progenitors to monocyte, macrophage, and dendritic
56	cell lineages (1, 2). IRF8 expression is significantly elevated in monocyte-dendritic cell
57	progenitors in mice and conversely, <i>Irf8^{-/-}</i> mice lack bone marrow resident macrophages,
58	dendritic cells, and plasmacytoid dendritic cells in lymphatic tissue (3-5). The role of IRF8 in the
59	generation of monocyte and dendritic cell progenitors is conserved in humans, as mutations
60	that impair IRF8 transcriptional activity are associated with immunodeficiency via decreased
61	monocyte and dendritic cell populations (6). Past work has shown that IRF8 is upregulated in
62	subsets of acute myeloid leukemia (AML) and correlates with poor prognosis in AML patients
63	(7). Moreover, we recently demonstrated that IRF8 immunohistochemistry stains monoblasts in
64	cases of acute monocytic leukemia and advanced chronic myelomonocytic leukemia, but is
65	negative in mature monocytes and granulocytes (8). Given this observation, IRF8 may hold
66	promise as a biomarker for additional malignancies derived from early monocyte and dendritic
67	cell precursors.

68

Myeloid sarcoma is a less common hematologic malignancy of immature monocyte and/or granulocyte populations that manifests as an extramedullary soft tissue mass (9). It is defined by the World Health Organization as a tumor of myeloid blasts that occurs at an anatomic location beyond the bone marrow (10). Myeloid sarcoma typically develops secondary to AML, although rare cases of isolated disease without bone marrow involvement or history of myeloid malignancy have been described (11). These tumors most commonly arise at the lymph nodes,

75	skin, soft tissues, and bone, and must cause effacement of local tissue in order to render a
76	myeloid sarcoma diagnosis (10). Due to the disparate sites of disease involvement, clinical
77	presentation is varied and pathology evaluation is critical for diagnosis. However, myeloid
78	sarcoma is notoriously difficult to diagnose, with an estimated misdiagnosis rate of 25-47% (12-
79	14). This diagnostic inaccuracy is a product of disease rarity, particularly in the absence of a
80	known myeloid disorder, as well as a dearth of markers for staining (15). Histologically, the
81	tumor demonstrates myeloid cell infiltration with myeloblasts or monoblasts (16). Of note,
82	lesions with granulocytic differentiation have features such as eosinophilic metamyelocytes
83	that aid in a myeloid sarcoma diagnosis, while tumors of monocytic origin lack these
84	characteristics and are typically more difficult to diagnose (12). Consequently, additional
85	biomarkers are needed to ameliorate the diagnostic challenges of this extramedullary
86	malignancy.

87

88 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematopoietic disorder of 89 plasmacytoid dendritic cells (17). BPDCN is a rare cancer, estimated to account for less than 1% of all hematologic malignancies, or roughly 700 cases annually in the United States (18, 19). In 90 91 90% of patients, BPDCN presents with skin manifestations and is later accompanied by 92 involvement of bone marrow, peripheral blood, and lymph nodes (20, 21). Progression to 93 systemic disease is rapid, and median survival is estimated to be between 12 and 14 months 94 (22). Diagnosis of BPDCN relies on clinical presentation, histological evaluation of the lesion, 95 and immunophenotyping (23). Due to cutaneous involvement that presents with blast cells in 96 the dermis, suspicion is often high for soft tissue tumors, T-cell leukemias/lymphomas, and NK-

97	cell leukemias/lymphomas (22). It can be difficult to differentiate these malignancies from						
98	BPDCN, and immunophenotyping is critical to validate the observed skin lesions are comprised						
99	of plasmacytoid dendritic cells rather than myeloid or lymphoid blasts (24). Additionally,						
100	expression of antigens expressed by other cell lineages, such as CD56 on NK/T-cell						
101	leukemia/lymphomas, and CD4 and CD123 on AMLs can make it difficult to render a definitive						
102	diagnosis (25). Thus, additional immunohistochemical markers in the diagnostic panel of BPDCN						
103	can help differentiate this malignancy from others with similar morphologic characteristics and						
104	clinical presentations.						
105							
106	We hypothesized that IRF8 may serve as a useful biomarker for myeloid sarcoma and BPDCN						
107	due to their prominent monoblastic and dendritic cell origin, respectively. Herein, we						
108	demonstrate that IRF8 is able to stain neoplastic cells of both myeloid sarcoma and BPDCN,						
109	even in cases lacking traditional markers for these malignancies. Importantly, IRF8 expression is						
110	absent in a panel of soft-tissue cancers that could potentially mimic myeloid sarcoma and						
111	BPDCN, as well as solid tumors. Our work demonstrates the utility for IRF8 in the identification						
112	of these rare hematologic malignancies that are in need of additional markers to aid in						
113	diagnosis.						
114							
115	2.0: Methods						
116	2.1: Human Tumor Samples and TMA Creation						
117	35 cases of myeloid sarcoma and 13 cases of BPDCN were obtained following approval by the						

118 Yale institutional review board. All cases were diagnosed by board-certified pathologists at the

119	Yale School of Medicine according to their WHO criteria and validated by a second reviewer at
120	outside institutions. Both a pan-cancer tissue microarray of 150 cases spanning 25 tumor
121	subtypes and 27 tissue-matched normal samples as well as a triple-negative breast cancer-
122	specific TMA of 97 cases were made in the Department of Pathology at the Yale School of
123	Medicine. All cases were previously diagnosed at Yale and utility of these biopsies in this study
124	was approved by the Yale institutional review board. In addition, we used specimens from
125	select sections of various previously published sarcoma-specific TMAs, including desmoplastic
126	small round cell tumor (n=30), Ewing sarcoma (n=24), synovial sarcoma (n=45), and
127	undifferentiated pleomorphic sarcoma (n=12).
128	
129	2.2: IHC Staining and Scoring
130	Immunohistochemistry (IHC) of all aforementioned samples and TMAs was performed using a
131	rabbit monoclonal IRF8 antibody (Anti-IRF8 ab207418 from Abcam, 1:900 dilution) as previously
132	described (8). We additionally stained myeloid sarcoma samples with both myeloperoxidase
133	(MPO rabbit polyclonal concentrate from Dako, 1:10 000 dilution) and CD34 (QBEND from
134	Ventana, Neat), and BPDCN samples with CD123 (9F5 from BD Biosciences, 1:50 dilution). Cases
135	that were double stained with IRF8 and lysozyme utilized the double-staining protocol on Bond
136	with lysozyme (polyclonal from Agilent, Neat). To perform staining, formalin-fixed, paraffin-
137	embedded tumor tissue sections were deparaffinized and rehydrated prior to antigen retrieval
138	and primary antibody incubation. Afterward, specimens were incubated with diaminobenzidine
139	(DAB) chromagen for primary antibody detection and counterstained with hematoxylin. All
140	stained samples were evaluated for both percentage of immunoreactive cells and staining

141	intensity (0, negative; 1+, weak; 2+, moderate; 3+, strong) (26). When possible for both TMAs						
142	and whole tissue sections, at least 3 non-adjacent fields containing tumor cells were evaluated						
143	for IRF8 staining. Only IRF8 nuclear staining of neoplastic cells was considered positive, as						
144	several samples demonstrated cytoplasmic staining of cancerous cells or nuclear staining of						
145	infiltrating lymphocytes. Nuclear reactivity at any intensity was denoted as positive for IRF8 and						
146	given as percentage of overall tumor cells in a sample. Percentage of positive cells within tumor						
147	was also scored for CD34 and MPO in all myeloid sarcoma cases.						
148							
149	2.3: TCGA Database Analysis						
150	Expression levels of IRF8 across different cancer types and their matched normal tissue were						
151	analyzed using Gene Expression Profiling Interactive Analysis (GEPIA), which utilizes global RNA-						
152	Seq data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx)						
153	databases. While TCGA contains expression data from 33 types of cancer, we collated this						
154	dataset to only analyze subtypes that were represented in our pan-cancer and sarcoma TMAs.						
155	We then determined the log2 fold change of IRF8 expression between cancerous and normal						
156	tissue, utilizing a fold-change threshold of 1 and a p-value cutoff of 0.01 (as determined by a						
157	one-way ANOVA) to identify significantly different IRF8 transcript abundance between these						
158	two groups.						
159							
160	3.0: Results						
161	3.1: IRF8 abundance is elevated in monocyte-derived myeloid sarcoma						

162 In order to investigate IRF8 expression in tumors of monocytic origin, we evaluated its abundance

163 in myeloid sarcoma, an extramedullary malignancy of neoplastic immature monocytes and/or 164 granulocytes (9). We performed immunohistochemical staining of 35 myeloid sarcoma patient 165 samples and concomitantly stained for CD34, a hematopoietic stem cell marker, and 166 myeloperoxidase (MPO), a myeloid marker. IRF8 was detectable in 24 of 35 (68.5%) of these 167 cases, and CD34 was often undetectable in cases with the greatest degree of IRF8 positivity 168 (Figure 1). Importantly, there were six cases for which IRF8 positivity was observed in the absence 169 of CD34 or MPO expression, suggesting that IRF8 is able to identify myeloid sarcomas of primarily 170 monocytic origin (Figure 2). In order to confirm monocytic origin of these blasts, double staining 171 with lysozyme was performed on select MPO-negative specimens with sufficient remaining 172 tissue. These showed blasts that were IRF8+ lysozyme+ as well as background scattered mature 173 monocytes that were IRF8- lysozyme+ (Figure 3).

174

175 <u>3.2: IRF8 is expressed in blastic plasmacytoid dendritic cell neoplasm</u>

176 After observing IRF8 upregulation in myeloid sarcoma, we next investigated IRF8 abundance in 177 blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematopoietic malignancy arising 178 from immature plasmacytoid dendritic cells (17). Staining of 13 BPDCN cases demonstrated 179 uniform IRF8 expression, with 13/13 (100%) samples showing positive IRF8 staining by 180 immunohistochemistry. Importantly, there were multiple cases that stained negative for CD123, 181 a marker commonly used in the diagnosis of BPDCN, but positive for IRF8 (Figure 4). This finding 182 suggests that IRF8 holds promise as a marker for multiple difficult-to-diagnose hematologic 183 malignancies of monocytic or dendritic cell origin.

185 <u>3.3: Assessment of IRF8 expression across different cancer types</u>

186 We next sought to evaluate IRF8 expression across additional tumor types and normal tissues in 187 order to validate that presence of IRF8 is specific to hematopoietic malignancies. Consequently, 188 we performed IRF8 staining of a pan-cancer TMA comprising 177 patient samples of both normal 189 and cancerous tissue across 11 tissue types and 25 cancer subtypes. IRF8 expression was negative 190 in all normal tissue samples and all but one tumor sample, which was a diffuse large B-cell 191 lymphoma of the testis (Table 1, Figure 5). We also sought to further evaluate IRF8 expression in 192 breast cancer, as our small cohort of breast cancers in the initial pan-cancer TMA were devoid of 193 triple-negative breast cancers (TNBCs). We additionally assessed IRF8 expression on a TMA of 97 194 TNBCs and observed that 2 (2.1%) of these tumors were IRF8-positive. The staining pattern for 195 these cases was weak and showed subset reactivity (Figure 5). In many samples, we observed 196 IRF8 staining of background lymphocytes that spared large, neoplastic cells.

197

198 We next analyzed publicly available expression data from The Cancer Genome Atlas (TCGA) to 199 further assess IRF8 expression between normal and cancerous tissues for malignancies included 200 in the TMA. In line with previous reports, IRF8 was significantly upregulated in acute myeloid 201 leukemia and diffuse large B-cell lymphoma samples relative to normal tissue (7). However, IRF8 202 mRNA expression was also increased in colon adenocarcinoma, stomach adenocarcinoma, and 203 testicular germ cell tumors (Figure 6). While these tumors were represented in our pan-cancer 204 TMA, we did not observe a similar upregulation of IRF8 protein in the neoplastic cells, but rather 205 in infiltrating lymphocytes (Table 1).

207 We next performed IRF8 staining on sarcoma TMAs of subtypes that may be considered in the 208 differential diagnosis of myeloid sarcoma or BPDCN. IRF8 expression was not observed in any of 209 the 111 soft-tissue tumors belonging to 4 subtypes of sarcomas in these TMAs, which included 210 desmoplastic small round cell tumor, Ewing sarcoma, synovial sarcoma, and undifferentiated 211 pleomorphic sarcoma (Table 2). These results indicate that IRF8 expression is specifically 212 upregulated in monocyte-derived soft-tissue tumors and can be utilized to identify myeloid 213 sarcomas that lack CD34 or MPO expression. Taken together, these findings suggest that 214 increased abundance of IRF8 has the potential to distinguish malignant cells across several cancer 215 types and is most significantly associated with hematologic malignancies. 216 217 4.0: Discussion 218 Malignancies derived from monoblasts are often difficult to diagnose, owing to their occasional 219 morphologic overlap with other malignancies as well as a dearth of reliable 220 immunohistochemical stains for these early hematopoietic progenitors (27). We recently 221 identified IRF8 as a sensitive and specific monoblast marker in cases of acute monocytic 222 leukemia (AMoLs) by demonstrating its strong correlation with aspirate blast count in AMoLs 223 (8). IRF8 is a transcription factor that upregulates genes critical for the differentiation of 224 monocytes, dendritic cells, and macrophages (2). Prior work has demonstrated that IRF8 225 expression peaks in monocyte and dendritic cell precursors, and thereafter remains high in 226 mature dendritic cells but rapidly decreases in mature monocytes, suggesting it will potently 227 stain immature monocytic/dendritic cell populations (3, 28). Herein, we have demonstrated

that IRF8 is expressed in multiple hematologic malignancies of monoblastic/dendritic cell origin
 and holds promise as a biomarker for these difficult-to-diagnose neoplasms.

230

231 Given our recent work demonstrating IRF8 as a reliable monoblast marker, we sought to 232 evaluate the utility of IRF8 in staining monocyte-derived hematopoietic cancers for which 233 clinical diagnosis is challenging and helpful tissue markers are lacking. We first stained for IRF8 234 in samples of myeloid sarcoma, an extramedullary tumor of mixed immature granulocyte and 235 monocyte origin (15). Myeloid sarcoma can rarely occur as an isolated disease but is most 236 commonly observed as a manifestation of acute myeloid leukemia, being reported in roughly 237 2.5-9.1% of AML patients (11). It is often difficult for pathologists to diagnose, particularly in the 238 absence of a previous AML diagnosis; prior studies have estimated that between 25-47% of 239 myeloid sarcoma cases are misdiagnosed, largely due to inadequate immunophenotyping of 240 the lesion (12-14). Consequently, we posited that IRF8 could be utilized to stain myeloid 241 sarcoma cases with prominent monoblast populations. IRF8 was able to stain a significant 242 proportion of myeloid sarcoma cases, including those negative for CD34 and MPO; these cases 243 that had previous/concurrent marrows did indeed demonstrate monocytic differentiation by 244 aspirate morphology with or without flow immunophenotypic support. Additionally, IRF8 did 245 not stain any other soft-tissue tumors on sarcoma TMAs representing some of the differential 246 diagnoses of myeloid sarcoma, including Ewing sarcoma, undifferentiated pleomorphic 247 sarcoma, desmoplastic small round cell tumor and synovial sarcoma (29). Thus, IRF8 can be 248 utilized as a biomarker for myeloid sarcoma and has the potential to improve diagnostic

accuracy of this less common hematologic malignancy, particularly for cases which are primarilyof monocytic origin.

251

252	We next evaluated the utility of IRF8 in staining malignant cells in blastic plasmacytoid dendritic
253	cell neoplasm (BPDCN). BPDCN is an aggressive, rare tumor derived from precursors of
254	plasmacytoid dendritic cells that often presents asymptomatically or with multiple bruise-like
255	cutaneous lesions before progressing to involve extracutaneous sites (20). In roughly 66% of
256	patients, BPDCN presents as stage IV disease at time of diagnosis, and median survival is
257	estimated to be between 12 and 14 months (22). BPDCN diagnosis is made on the basis of
258	clinical features, morphological findings, and immunophenotype. Diagnosis is challenging, and
259	BPDCN is often difficult to distinguish from soft-tissue tumors, AML, and T-cell
260	leukemias/lymphomas. This is due to both an overlap in immunophenotyping as well as the
261	common lymphoid-like morphology of BPDCN blasts that leads to a false suspicion of
262	lymphoma (30). Given the dendritic cell lineage of BPDCN blasts and the diagnostic difficulties
263	associated with the disease, we hypothesized that IRF8 could be a useful tool in staining
264	neoplastic BPDCN cells. All 13 samples we obtained of this highly rare tumor were strongly
265	positive for IRF8 staining. Additionally, several of these IRF8-positive cases were negative for
266	CD123, a marker commonly used for BPDCN, suggesting that IRF8 may be a useful marker to
267	add to the diagnostic panel for this aggressive hematopoietic malignancy (31).
268	

Following the identification of positive IRF8 staining in myeloid sarcoma and BPDCN, we sought
 to determine if its expression is specific to cancers of hematologic origin. We showed that IRF8

271 did not stain any solid tumors or normal tissue on a pan-cancer TMA comprising 25 cancer 272 subtypes. However, global expression data from The Cancer Genome Atlas (TCGA) suggested 273 that IRF8 is transcriptionally upregulated in several carcinomas relative to normal tissue, 274 particularly colon adenocarcinoma, stomach adenocarcinoma, and testicular germ cell tumors, 275 all of which were represented in our TMA. In contrast to this TCGA data, prior reports have 276 indicated that IRF8 expression is preferentially decreased in both colon and gastric cancer 277 samples relative to noncancerous tissue, through mechanisms such as increased promoter 278 methylation (32, 33). This discrepancy highlights the discordance that can be observed between 279 TCGA data and primary patient samples. Moreover, while breast cancers represented in the pan-cancer TMA were uniformly IRF8-negative, we performed additional staining on a TMA 280 281 specific for triple-negative breast cancers (TNBCs) due to a recent study documenting increased 282 IRF8 expression in estrogen receptor-negative breast cancers (34). However, only rare cases 283 (2.1%) of the TNBCs in this TMA stained weakly positive for IRF8. This observation is potentially 284 due to the fact that these investigators found IRF8 expression to be increased specifically in 285 early-stage ER-negative cancers, which may not have been as well represented on the TMA as 286 advanced disease. Importantly, and in line with recent work, IRF8 upregulation was most 287 significantly associated with AML and diffuse large b-cell lymphoma in the TCGA dataset, 288 further indicating that IRF8 likely has greatest utility as a marker of hematopoietic neoplasms 289 (7).

290

291 In this study, we demonstrate that IRF8 can be used to identify monocyte and dendritic cell-292 derived malignancies that are prone to misdiagnosis due to a scarcity of specific markers. Our

293	study is limited by the relatively few cases of BPDCN. In addition, since B-cell lymphomas are							
294	also positive for IRF8, the marker does not help to differentiate among hematopoietic tumors.							
295	Further validation of these findings will be critical in order to integrate IRF8 staining into							
296	pathologists' workflow for diagnosis of these diseases. Additionally, future studies should build							
297	upon this work by determining if differential IRF8 expression correlates with poor prognosis or							
298	response to therapy in the diseases it stains. While this will likely prove challenging due to the							
299	rarity of both myeloid sarcoma and BPDCN, identifying additional prognostic markers for these							
300	diseases is crucial, particularly given the lack of data regarding survival differences between							
301	granulocyte-predominant and monocyte-predominant myeloid sarcoma (35). IRF8 thus may							
302	hold promise not only as a marker for diagnosis but also as a prognostic indicator that guides							
303	treatment intervention for these rare hematopoietic neoplasms.							
304								
305	Acknowledgements							
306	We acknowledge Amos Brooks and Lori Charette from Yale Pathology Tissue Services for their							
307	invaluable experience and aid with immunohistochemical studies as well as tissue procurement							
308	and processing.							
309								
310	Conflict of Interest							
311	The authors have disclosed that they have no significant relationships with, or financial interest							
312	in any commercial companies pertaining to this article.							
313								

314 Ethics Approval and Consent to Participate

315	The study was performed in accordance with the Declaration of Helsinki. The study was					
316	approved by an internal review board (local ethics committee HIC protocol #2000023891).					
317						
318	Author Contributions					
319	D.C.M., S.G.K., and M.L.X. contributed equally in conception and design. D.C.M., M.L.X, and G.P.					
320	carried out data analysis. W.W. contributed additional cases. D.C.M. wrote the manuscript with					
321	significant contributions from M.L.X. and S.G.K. All authors edited the manuscript.					
322						
323	Funding					
324	The authors have no funding sources to declare.					
325						
326	Data Availability					
327	The tissue sections analyzed during this study are available from the corresponding author					
328	upon request. TCGA data analyzed during this study are publicly available using the GEPIA					
329	online resource.					
330						
331						
332						
332333						
332333334						
332333334335						

337 References

- 1. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K. ICSBP directs bipotential
- 339 myeloid progenitor cells to differentiate into mature macrophages. Immunity. 2000;13(2):155-
- 340 **65**.
- 341 2. Kurotaki D, Osato N, Nishiyama A, Yamamoto M, Ban T, Sato H, et al. Essential role of the
- 342 IRF8-KLF4 transcription factor cascade in murine monocyte differentiation. Blood.
- 343 2013;121(10):1839-49.
- 344 3. Kurotaki D, Yamamoto M, Nishiyama A, Uno K, Ban T, Ichino M, et al. IRF8 inhibits C/EBPα
- 345 activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils.
- 346 Nat Commun. 2014;5:4978.
- 347 4. Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN
- 348 regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells.
- 349 J Immunol. 2003;170(3):1131-5.
- 350 5. Yamamoto M, Kato T, Hotta C, Nishiyama A, Kurotaki D, Yoshinari M, et al. Shared and
- 351 distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development. PLoS
- 352 One. 2011;6(10):e25812.
- 353 6. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8
- 354 mutations and human dendritic-cell immunodeficiency. N Engl J Med. 2011;365(2):127-38.
- 355 7. Liss F, Frech M, Wang Y, Giel G, Fischer S, Simon C, et al. IRF8 Is an AML-Specific Susceptibility
- 356 Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers (Basel).
- 357 2021;13(4).

- 8. Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic
- 359 Leukemias. Am J Surg Pathol. 2021;45(10):1391-8.
- 360 9. Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, et al. Myeloid sarcomas: a
- histologic, immunohistochemical, and cytogenetic study. Diagn Pathol. 2007;2:42.
- 362 10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008
- 363 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute
- leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
- 365 11. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid
- 366 leukemia. Blood. 2011;118(14):3785-93.
- 367 12. Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid Sarcoma:
- 368 Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263-7.
- 369 13. Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, et al. Is there a "gold"
- 370 standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother.
- 371 2013;67(1):72-7.
- 372 14. Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma:
- 373 report of two cases and a review of 72 cases in the literature. Cancer. 2002;94(6):1739-46.
- 15. Magdy M, Abdel Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M. Myeloid
- 375 Sarcoma. Oncol Res Treat. 2019;42(4):224-9.
- 376 16. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-
- 377 pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340-
- **378 50**.

- 379 17. Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, et al. Molecular
- 380 profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests
- 381 selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606-16.
- 382 18. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and
- 383 characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-
- 384 **6**9.
- 385 19. Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic
- 386 plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
- 387 Haematologica. 2013;98(2):239-46.
- 388 20. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of
- 389 blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series
- 390 of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
- 391 21. Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, et al. Blastic plasmacytoid
- dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-86.
- 393 22. Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch
- 394 Pathol Lab Med. 2014;138(4):564-9.
- 395 23. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm.
- Hematology Am Soc Hematol Educ Program. 2016;2016(1):16-23.
- 397 24. Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, et al. Blastic plasmacytoid
- 398 dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and
- 399 HyperCVAD therapy. Am J Hematol. 2016;91(3):283-6.

400	25. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al. Extended					
401	diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-					
402	36.					
403	26. Parris TZ, Aziz L, Kovács A, Hajizadeh S, Nemes S, Semaan M, et al. Clinical relevance of					
404	breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma. BMC					
405	Cancer. 2014;14:324.					
406	27. Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ. Morphological					
407	evaluation of monocytes and their precursors. Haematologica. 2009;94(7):994-7.					
408	28. Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, et al. IRF8					
409	Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional					
410	and Plasmacytoid Dendritic Cells, Respectively. Immunity. 2016;45(3):626-40.					
411	29. Marwah N, Bhutani N, Budhwar A, Sen R. Isolated myeloid sarcoma of the temporal bone:					
412	As the first clinical manifestation of acute myeloid leukemia in a patient of down's syndrome.					
413	Int J Surg Case Rep. 2019;58:77-80.					
414	30. Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, et al. How should we					
415	diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv.					
416	2019;3(24):4238-51.					
417	31. Laribi K, Denizon N, Besançon A, Farhi J, Lemaire P, Sandrini J, et al. Blastic Plasmacytoid					
418	Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. Biol Blood Marrow					
419	Transplant. 2016;22(8):1357-67.					

420	32. Ibrahim MLL	, K. IRF8 deficienc	y in colonic epithelial cells	promotes inflammation-mediated

- 421 colon tumorigenesis and myeloid-derived suppressor cell differentiation. J Immunol.
- 422 2017;198(66.20).
- 423 33. Yamashita M, Toyota M, Suzuki H, Nojima M, Yamamoto E, Kamimae S, et al. DNA
- 424 methylation of interferon regulatory factors in gastric cancer and noncancerous gastric
- 425 mucosae. Cancer Sci. 2010;101(7):1708-16.
- 426 34. Gatti G, Betts C, Rocha D, Nicola M, Grupe V, Ditada C, et al. High IRF8 expression correlates
- 427 with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative
- 428 breast cancer. Breast Cancer Res. 2021;23(1):40.
- 429 35. Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options.
- 430 Ther Adv Hematol. 2011;2(5):309-16.
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441

442 Figure/table legends

443	Figure 1: IRF8 expression in myeloid s	arcoma.	Heat map of myeloid	sarcoma cases based	on
-----	--	---------	---------------------	---------------------	----

- 444 percent positivity of tumor cells for IRF8, CD34, or MPO by immunohistochemistry.
- 445
- 446 **Figure 2: Representative case of myeloid sarcoma at 2X, 20X magnification.** This tumor shows
- 447 strong IRF8 expression in the monoblastic population of tumor cells and MPO staining in the
- 448 granulocytic population (Case 8 in Figure 1). IRF8 expression is dimly observed in the mantle
- 449 zone B cells adjacent to neoplastic cells.
- 450
- 451 **Figure 3: IRF8 and lysozyme staining in monocytic malignancies.** Double stain with IRF8
- 452 (brown) and lysozyme (red) highlights double-positive monoblasts in a case of myeloid sarcoma
- 453 (Case 1) and lysozyme single-positive monocytes in the skin (Case 2).
- 454
- Figure 4: Expression patterns of BPDCN in three representative patients. Case 1 shows a midchest skin biopsy. Case 2 shows a bone marrow biopsy. Case 3 shows a left chest skin biopsy. All
 images taken at 200x magnification.
- 458

459 **Figure 5: Representative cases of IRF8 immunohistochemistry from pan-cancer TMA.** Case 1

- 460 shows a squamous cell skin carcinoma with IRF8 staining of infiltrating lymphocytes but not
- 461 neoplastic cells. Case 2 shows a gastric adenocarcinoma with a similar staining pattern to Case
- 462 1. Case 3 shows a testicular lymphoma with IRF8 staining of large, polymorphic tumor cells.
- 463 Case 4 shows a representative case of an IR8-positive TNBC.

464

465	Figure 6: IRF8 expression in cancerous tissues (red) and normal tissues (gray). Box plots
466	marked with a red asterisk indicate a statistically significant difference (p < .05) between tumor
467	and normal tissue. BLCA – Bladder Urothelial Carcinoma, BRCA – Breast Invasive Carcinoma,
468	COAD – Colon Adenocarcinoma, DLBC – Lymphoid Neoplasm Diffuse Large B-Cell Lymphoma,
469	KIRP – Kidney Renal Papillary Cell Carcinoma, LAML – Acute Myeloid Leukemia, LIHC – Liver
470	Hepatocellular Carcinoma, LUAD – Lung Adenocarcinoma, LUSC – Lung Squamous Cell
471	Carcinoma, OV – Ovarian Serous Cystadenocarcinoma, SARC – Sarcoma,
472	STAD – Stomach Adenocarcinoma, TGCT – Testicular Germ Cell Tumors.
473	

474 **Table 1:** IRF8 expression in normal tissues and malignancies of different origins included in a

475 pan-cancer TMA.

Tissue	Subtype	Negative	Positive	Total
Bladder	Normal Bladder	3 (100%)	0	3
	Papillary Transitional Cell Carcinoma	1 (100%)	0	1
	Papillary Urothelial Carcinoma	4 (100%)	0	4
	Serous Adenocarcinoma	1 (100%)	0	1
	Urothelial Carcinoma	10 (100%)	0	10
Breast	Ductal Carcinoma	9 (100%)	0	9
	Lobular Carcinoma	1 (100%)	0	1
Colon	Normal Colon	2 (100%)	0	2
	Adenocarcinoma	13 (100%)	0	13
Kidney	Normal Kidney	3 (100%)	0	3
	Papillary Renal Cell Carcinoma	10 (100%)	0	10
	Renal Cell Carcinoma	4 (100%)	0	4
Liver	Normal Liver	4 (100%)	0	4
	Hepatocellular Carcinoma	14 (100%)	0	14
	Mixed Hepatocholangiocarcinoma	1 (100%)	0	1
Lung	Normal Lung	2 (100%)	0	2
	Adenocarcinoma	7 (100%)	0	7

	Neuroendocrine Carcinoma	1 (100%)	0	1
	Squamous Cell Carcinoma	8 (100%)	0	8
Ovary	Normal Ovary	4 (100%)	0	4
	Adenocarcinoma	12 (100%)	0	12
Pancreas	Normal Pancreas	3 (100%)	0	3
	Adenocarcinoma	1 (100%)	0	1
	Endocrine Carcinoma	12 (100%)	0	12
	Neuroendocrine Carcinoma	2 (100%)	0	2
Skin	Normal Skin	2 (100%)	0	2
	Squamous Cell Carcinoma	14 (100%)	0	14
Stomach	Normal Stomach	2 (100%)	0	2
	Adenocarcinoma	10 (100%)	0	10
Testis	Normal Testis	2 (100%)	0	2
	Embryonal Carcinoma	1 (100%)	0	1
	Leydig Cell Carcinoma	2 (100%)	0	2
	Lymphoma	0	1 (100%)	1
	Mixed Germ Cell Carcinoma	6 (100%)	0	6
	Seminoma	5 (100%)	0	5

Table 2: IRF8 expression in different types of sarcoma included in sarcoma-specific TMAs.

Sarcoma Type	Negative	Positive	Total
Desmoplastic small round cell tumor	30 (100%)	0	30
Ewing sarcoma	24 (100%)	0	24
Synovial sarcoma	45 (100%)	0	45
Undifferentiated pleomorphic sarcoma	12 (100%)	0	12







H&E





























CASE 1

CASE 2

CASE 3







